DISEASE INDICATIONS: Psoriasis

MANUFACTURER: Boehringer Ingelheim

USAGE: Intravenous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Spevigo (spesolimab-sbzo) is a humanized monoclonal antibody that targets the protein interleukin-36 (IL-36) to treat moderate-to-severe plaque psoriasis in adults. The medication is administered via intravenous infusion and inhibits the formation of proinflammatory cytokines that contribute to the development of psoriasis.